The attempt to develop a causal treatment against the progression of Alzheimer’s disease is an unparalleled series of nearly two decades of failures in drug development. However, the failures also allowed much better insights in the design of a future development programme for anti-Alzheimer medications. Peter Schueler at ICON Clinical Research investigates how these insights are to be used to end the series of failures with novel targets and molecules.
